Lp(a) With CCTA Assessed Parameters and Clinical Outcomes (CHART-ACCORD)

Fudan University

Status: Unknown

Conditions: Coronary Artery Disease

Treatments: Diagnostic Test: Coronary CTA

Study type: Observational

Funder types: Other

Identifiers

NCT05323227

CHART20220404

Details and patient eligibility

About

Lipoprotein(a) [Lp(a)] is a risk factor for cardiovascular events, although the underlying mechanism remains unclear. This study evaluated the relationship between Lp(a) and high-risk attributes (HRA) by coronary computed tomography angiography (CCTA) as well as their prognostic value.

Enrollment: 378 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with Lp(a) meaured within 1 week of CCTA examination.

Exclusion criteria

• unstable angina pectoris
• acute myocardial infarction
• New York Heart Association class III-IV heart failure
• with a history of bypass surgery
• active infection
• respiratory failure
• chronic kidney disease (estimated glomerular filtration rate [eGFR] <60 ml/min/1.73 m2)
• liver dysfunction (liver enzyme >3 upper reference limit [URL] or bilirubin >2 URL)
• malignancy
• systemic connective tissue disease
• poor CCTA imaging quality not suitable for analysis
• other situations not suitable for the study

Trial design

378 participants in 2 patient groups

Group 1

Description:

Patients with Lp(a) \<60mg/dL

Treatment:

Diagnostic Test: Coronary CTA

Group 2

Description:

Patients with Lp(a) ≥60 mg/dL

Treatment:

Diagnostic Test: Coronary CTA